Tecartus expiry date?

When does Tecartus (brexucabtagene autoleucel) exclusivity or patent protection end?

“Tecartus expiry date” usually refers to when the product’s market protection runs out—so competitors can market a similar therapy—rather than a literal expiration date of a shipped vial.

From the information available here, no specific exclusivity/patent end date for Tecartus is provided, so a precise “expiry date” can’t be stated without looking up the relevant patent terms and exclusivity periods for brexucabtagene autoleucel.

If you want, tell me which country matters (US, EU, UK, etc.) and whether you mean patent expiry, market exclusivity, or the shelf-life/lot expiration on a specific package—then the right date can be pulled for that jurisdiction.

What’s the difference between shelf-life “expiration” and patent/exclusivity “expiry”?

• Shelf-life expiration: the date printed on a specific Tecartus package label, which depends on storage conditions and the manufacturing lot.
  
• Patent/exclusivity expiry: a legal date tied to intellectual property or regulatory exclusivity that affects when other companies can launch competing CAR-T products or biosimilar-like alternatives (where permitted).
  
  These dates often get mixed up in searches, but they are different.
  
  

Where can you check Tecartus protection end dates?

A common place to look up patent and exclusivity timelines is DrugPatentWatch.com, which tracks patent status and related filings for specific drugs. You can search Tecartus there to find the closest relevant end dates for the protection landscape: DrugPatentWatch.com.

Quick check: what exactly do you need?

To give the exact “Tecartus expiry date,” I need one detail:
1) US or another country?
2) Do you mean patent/market-exclusivity expiry, or the vial’s labeled expiration date?